Shares of Haleon PLC Sponsored ADR (NYSE:HLN – Get Free Report) have been assigned an average rating of “Hold” from the eleven analysts that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation, three have assigned a buy recommendation and two have issued a strong buy recommendation on the company.
Several research analysts have recently weighed in on the stock. Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Rothschild & Co Redburn cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 16th. Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research note on Thursday, August 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a report on Tuesday, June 30th. Finally, Zacks Research cut shares of Haleon from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 21st.
Read Our Latest Stock Report on HLN
Institutional Investors Weigh In On Haleon
Haleon Stock Up 0.1%
Shares of NYSE:HLN opened at $9.94 on Friday. Haleon has a 52-week low of $8.65 and a 52-week high of $11.28. The stock has a market cap of $43.76 billion, a P/E ratio of 25.47, a PEG ratio of 1.99 and a beta of 0.12. The business has a fifty day moving average of $9.56 and a two-hundred day moving average of $9.85. The company has a quick ratio of 0.52, a current ratio of 0.69 and a debt-to-equity ratio of 0.38.
Haleon Cuts Dividend
The firm also recently disclosed a dividend, which will be paid on Thursday, September 17th. Investors of record on Friday, August 14th will be issued a $0.0642 dividend. The ex-dividend date is Friday, August 14th. This represents a yield of 127.0%. Haleon’s dividend payout ratio is currently 64.10%.
About Haleon
Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.
The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.
Featured Stories
- Five stocks we like better than Haleon
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
